2-amino-5-phosphonovalerate has been researched along with Chromosomal Triplication in 2 studies
2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Joshi, K | 1 |
| Shen, L | 1 |
| Cao, F | 1 |
| Dong, S | 1 |
| Jia, Z | 1 |
| Cortez, MA | 1 |
| Snead, OC | 1 |
| Kleschevnikov, AM | 1 |
| Belichenko, PV | 1 |
| Villar, AJ | 1 |
| Epstein, CJ | 1 |
| Malenka, RC | 1 |
| Mobley, WC | 1 |
2 other studies available for 2-amino-5-phosphonovalerate and Chromosomal Triplication
| Article | Year |
|---|---|
Kcnj6(GIRK2) trisomy is not sufficient for conferring the susceptibility to infantile spasms seen in the Ts65Dn mouse model of down syndrome.
Topics: 2-Amino-5-phosphonovalerate; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relatio | 2018 |
Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome.
Topics: 2-Amino-5-phosphonovalerate; Animals; Cognition Disorders; Crosses, Genetic; Dentate Gyrus; Disease | 2004 |